Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Hematology and Oncology Specialists |
---|---|
Information provided by: | Hematology and Oncology Specialists |
ClinicalTrials.gov Identifier: | NCT00107913 |
This study is designed to evaluate the efficacy and safety of single agent Doxil in the treatment of patients with refractory ITP (Idiopathic Thrombocytopenic Purpura).
Condition | Intervention | Phase |
---|---|---|
Autoimmune Thrombocytopenic Purpura |
Drug: Doxil |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Phase II Study of Doxil in the Treatment of Patients With Refractory Idiopathic Thrombocytopenic Purpura |
Estimated Enrollment: | 10 |
Study Start Date: | September 2001 |
Estimated Study Completion Date: | April 2005 |
Eligible patients will receive Doxil 20 mg/m2 IV over 1 hour every 2 weeks. Treatment will be continued for 1 course beyond return of the platelet count to normal with a maximum of 18 courses.
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Louisiana | |
Hematology and Oncology Specialists | Recruiting |
Metairie, Louisiana, United States, 70006 | |
Contact: Mary Ann Ostroske, RN 504-894-7115 ext 221 mostroske1@salco.net | |
Contact: Avri Haggerty, MT 504-883-2968 ahaggerty@salco.net | |
Principal Investigator: Thomas M Cosgriff, MD |
Principal Investigator: | Thomas M Cosgriff, MD | Hematology and Oncology Specialists |
Study ID Numbers: | HOS1 |
Study First Received: | April 11, 2005 |
Last Updated: | June 23, 2005 |
ClinicalTrials.gov Identifier: | NCT00107913 |
Health Authority: | United States: Institutional Review Board |
Immune Thrombocytopenic Purpura |
Purpura Autoimmune Diseases Hematologic Diseases Blood Coagulation Disorders Blood Platelet Disorders Hemostatic Disorders Doxorubicin |
Purpura, Thrombocytopenic Signs and Symptoms Thrombocytopathy Thrombocytopenia Hemorrhagic Disorders Thrombocytopenic purpura, autoimmune Purpura, Thrombocytopenic, Idiopathic |
Skin Manifestations Immune System Diseases Antineoplastic Agents |
Therapeutic Uses Antibiotics, Antineoplastic Pharmacologic Actions |